OMID C FAROKHZAD, MD
Anesthesiologist Assistant at Francis St, Boston, MA
License number
Massachusetts 216083
Category
Osteopathic Medicine
Type
Anesthesiology
Address
Address
2
75 Francis St, Boston, MA 02115
111 Cypress St, Brookline, MA 02445
111 Cypress St, Brookline, MA 02445
Phone
(617) 732-8210
(857) 307-0896
(857) 307-0896
Organization information
See more information about OMID C FAROKHZAD at bizstanding.comOmid C. Farokhzad
14 Heron St APT 209, Roslindale, MA 02131
Phone:
(617) 323-6932 (Phone)
Email:
SIC:
6022 - State Commercial Banks
Professional information
Dr. Omid C Farokhzad, Boston MA - MD (Doctor of Medicine)
Specialties:
Pain Medicine
Address:
75 Francis St, Boston 02115
(617) 732-8210 (Phone)
Pain Management Center
850 Boylston St STE 320, Chestnut Hill 02467
(617) 732-9060 (Phone)
(617) 732-8210 (Phone)
Pain Management Center
850 Boylston St STE 320, Chestnut Hill 02467
(617) 732-9060 (Phone)
Certifications:
Anesthesiology, 2006, Pain Medicine, 2009
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
75 Francis St, Boston 02115
Pain Management Center
850 Boylston St STE 320, Chestnut Hill 02467
Brigham and Women's Hospital
75 Francis St, Boston 02115
Pain Management Center
850 Boylston St STE 320, Chestnut Hill 02467
Brigham and Women's Hospital
75 Francis St, Boston 02115
Education:
Medical School
Boston University School Of Medicine
Graduated: 1999
Beth Israel Deaconess Med Center
Brigham and Women's Hospital
Boston University School Of Medicine
Graduated: 1999
Beth Israel Deaconess Med Center
Brigham and Women's Hospital
Endothelial Basement Membrane Targeting Peptide Ligands
US Patent:
2011014, Jun 16, 2011
Filed:
Dec 15, 2010
Appl. No.:
12/969345
Inventors:
Robert S. Langer - , US
Omid C. Farokhzad - Chestnut Hill MA, US
Juliana M. Chan - Cambridge MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Juliana M. Chan - Cambridge MA, US
International Classification:
A61K 38/08, C07K 7/06, A61P 35/00, A61P 27/02, A61P 9/10, A61P 7/00, G01N 33/68
US Classification:
514 14, 530329, 514 217, 514 192, 514 133, 514 172, 514 216, 530327, 435 78
Abstract:
Peptides that selectively bind to antigens exposed in vascular disease or dysfunction have been identified by biopanning a phage library. The ligands are useful when attached to a substrate to be in contact with endothelial surfaces, especially those where drug delivery is utilized, such as following angioplasty, with release from a drug delivery reservoir in a medical device such as a stent, or by administration intravenously in the form of nano or microparticles, although the peptides may also be used with other medical devices or substrates, for targeting or to increase adhesion to endothelial surfaces. The nanoparticle technology can be used to treat injured vasculature, a clinical problem of primary importance. The targeted nanoparticles are also useful in the treatment of other diseases and disorders such as oncologic and regenerative diseases and indications where neoangiogenesis is commonly observed.
Oligonucleotide Systems For Targeted Intracellular Delivery
US Patent:
2010014, Jun 10, 2010
Filed:
Aug 6, 2007
Appl. No.:
12/376005
Inventors:
Omid C. Farokhzad - Chestnut Hill MA, US
Robert S. Langer - Newton MA, US
Frank Alexis - Brighton MA, US
Robert S. Langer - Newton MA, US
Frank Alexis - Brighton MA, US
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K 31/7052, C12Q 1/68, C07H 21/00, C12N 5/00, A61P 35/00
US Classification:
514 44 R, 435 6, 536 221, 435325
Abstract:
The present invention provides methods for deriving oligonucleotides for specific internal delivery to one or more target cell types (e.g., cancer cells). The method generally includes selecting at least once with a target cell type to provide a plurality of internalizing oligonucleotides for the target cell type, and in some embodiments, counter-selecting at least once with a non-target cell type to provide a plurality of oligonucleotides that do not bind to features present in the non-target cell type. Therapeutic and diagnostic compositions including the oligonucleotides, and methods of treatment are also provided.
Nicotine Immunonanotherapeutics
US Patent:
8591905, Nov 26, 2013
Filed:
Apr 22, 2009
Appl. No.:
12/428388
Inventors:
Ulrich von Andrian - Chestnut Hill MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Frank Alexis - Greenville SC, US
Matteo Iannacone - Boston MA, US
Pamela Basto - Somerville MA, US
Jinjun Shi - Boston MA, US
Elliott Ashley Moseman - Jamaica Plain MA, US
Robert S. Langer - Newton MA, US
Elena Tonti - Riccione, IT
Omid C. Farokhzad - Chestnut Hill MA, US
Frank Alexis - Greenville SC, US
Matteo Iannacone - Boston MA, US
Pamela Basto - Somerville MA, US
Jinjun Shi - Boston MA, US
Elliott Ashley Moseman - Jamaica Plain MA, US
Robert S. Langer - Newton MA, US
Elena Tonti - Riccione, IT
Assignee:
The Brigham and Women's Hospital, Inc. - Boston MA
President and Fellows of Harvard College - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
President and Fellows of Harvard College - Cambridge MA
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K 39/00, A61K 47/00
US Classification:
4241841, 4242781
Abstract:
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. For example, the present invention nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.
Nanostructures For Drug Delivery
US Patent:
8603532, Dec 10, 2013
Filed:
Oct 20, 2009
Appl. No.:
13/122615
Inventors:
Stephen J. Lippard - Cambridge MA, US
Shanta Dhar - Athens GA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Frank X. Gu - Waterloo, CA
Nagesh Kolishetti - Athens GA, US
Shanta Dhar - Athens GA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Frank X. Gu - Waterloo, CA
Nagesh Kolishetti - Athens GA, US
Assignee:
Massachusetts Institute of Technology - Cambridge MA
The Brigham and Women's Hospital, Inc. - Boston MA
The Brigham and Women's Hospital, Inc. - Boston MA
International Classification:
A61K 9/14, A61K 9/51
US Classification:
424489
Abstract:
The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor.
Controlled Release Nanoparticle Having Bound Oligonucleotide For Targeted Delivery
US Patent:
7727969, Jun 1, 2010
Filed:
Jun 6, 2003
Appl. No.:
10/456978
Inventors:
Omid C. Farokhzad - Boston MA, US
Sang Yong Jon - Cambridge MA, US
Robert S. Langer - Newton MA, US
Sang Yong Jon - Cambridge MA, US
Robert S. Langer - Newton MA, US
Assignee:
Massachusetts Institute of Technology - Cambridge MA
International Classification:
A61K 31/7088, A61K 9/14, C12Q 1/68, C12N 11/08, C12N 11/04, G01N 33/545, G01N 33/549, A61K 38/00, C07K 17/04, C07K 17/08
US Classification:
514 44R, 424486, 424489, 435 6, 435180, 435182, 436531, 436535, 514 2, 530817
Abstract:
The present invention relates to a conjugate that includes a nucleic acid ligand bound to a controlled release polymer system, a pharmaceutical composition that contains the conjugate, and methods of treatment using the conjugate. The controlled release polymer system includes an agent such as a therapeutic, diagnostic, prognostic, or prophylactic agent. The nucleic acid ligand that is bound to the controlled release polymer system, binds selectively to a target, such as a cell surface antigen, and thereby delivers the controlled release polymer system to the target.
Vaccine Nanotechnology
US Patent:
2010023, Sep 16, 2010
Filed:
Oct 12, 2008
Appl. No.:
12/681814
Inventors:
Ulrich H. Von Andrian - Chestnut Hill MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Robert S. Langer - Newton MA, US
Tobias Junt - Schomdorf, DE
Ashley Moseman - Jamaica Plain MA, US
Liangfang Zhang - Cambridge MA, US
Pamela Basto - Somerville MA, US
Matteo Iannacone - Boston MA, US
Frank Alexis - Brighton MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Robert S. Langer - Newton MA, US
Tobias Junt - Schomdorf, DE
Ashley Moseman - Jamaica Plain MA, US
Liangfang Zhang - Cambridge MA, US
Pamela Basto - Somerville MA, US
Matteo Iannacone - Boston MA, US
Frank Alexis - Brighton MA, US
International Classification:
A61K 9/127, A61K 9/14, A61K 39/00
US Classification:
424450, 424489, 4241841, 977773, 977906, 977907
Abstract:
The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at least one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
Magnetically Sensitive Drug Carriers And Delivery Devices
US Patent:
2011019, Aug 11, 2011
Filed:
Feb 11, 2010
Appl. No.:
12/704092
Inventors:
Florian Niklas Ludwig - Ebikon, CH
Syed Faiyaz Ahmed Hossainy - Hayward CA, US
Bjorn Svensson - Gilroy CA, US
Adam Sharkawy - San Jose CA, US
Michael J. Cima - Winchester MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Jesus Magana - Redwood City CA, US
Randolf Von Oepen - Los Altos Hills CA, US
Mina Chow - Campbell CA, US
Travis R. Yribarren - San Mateo CA, US
Kevin J. Ehrenreich - San Francisco CA, US
Syed Faiyaz Ahmed Hossainy - Hayward CA, US
Bjorn Svensson - Gilroy CA, US
Adam Sharkawy - San Jose CA, US
Michael J. Cima - Winchester MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Jesus Magana - Redwood City CA, US
Randolf Von Oepen - Los Altos Hills CA, US
Mina Chow - Campbell CA, US
Travis R. Yribarren - San Mateo CA, US
Kevin J. Ehrenreich - San Francisco CA, US
Assignee:
ABBOTT CARDIOVASCULAR SYSTEMS INC. - Santa Clara CA
International Classification:
A61N 2/00
US Classification:
600 12, 600 9
Abstract:
Apparatuses for delivering compositions of matter comprising a magnetically sensitive drug carrier and a related drug and methods for causing the drug carriers to localize within the patient using an internal or external magnetic field are described.
Amphiphilic Compound Assisted Nanoparticles For Targeted Delivery
US Patent:
2010020, Aug 12, 2010
Filed:
Oct 5, 2009
Appl. No.:
12/573591
Inventors:
Liangfang ZHANG - San Diego CA, US
Frank X. GU - Waterloo, CA
Frank ALEXIS - GREENVILLE SC, US
Robert S. LANGER - Newton MA, US
Omid C. FAROKHZAD - Chestnut Hill MA, US
Frank X. GU - Waterloo, CA
Frank ALEXIS - GREENVILLE SC, US
Robert S. LANGER - Newton MA, US
Omid C. FAROKHZAD - Chestnut Hill MA, US
Assignee:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY - Cambridge MA
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - Boston MA
International Classification:
A61K 9/14, A61K 38/19, A61K 39/00, A61K 38/02, A61K 31/7088, A61K 31/565, A61K 31/337, A61P 9/10, A61P 35/00
US Classification:
424487, 424484, 424486, 424 851, 4241841, 514 12, 514 44 R, 514182, 514449
Abstract:
The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
Polymer-Encapsulated Reverse Micelles
US Patent:
8193334, Jun 5, 2012
Filed:
Oct 5, 2009
Appl. No.:
12/573411
Inventors:
Liangfang Zhang - San Diego CA, US
Robert S. Langer - Newton MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Robert S. Langer - Newton MA, US
Omid C. Farokhzad - Chestnut Hill MA, US
Assignee:
The Brigham and Women's Hospital - Boston MA
Massachusetts Institute of Technologoy - Cambridge MA
Massachusetts Institute of Technologoy - Cambridge MA
International Classification:
C07H 21/04, C07H 21/02, C12N 15/63, A61K 48/00, A61K 43/00
US Classification:
536 245, 536 231, 536 2431, 536 2433, 4353201, 514 44, 424 111
Abstract:
A method for encapsulating nucleic acids, particularly siRNAs, shRNAs, microRNAs, gene therapy plasmids, and other oligonucleotides in biodegradable polymers is disclosed, whereby the nucleic acids are formulated into reverse micelles composed of non-toxic and/or naturally-occurring lipids prior to nanoparticle formation by nanoprecipitation. This method can be coupled to other techniques that improve intracellular drug targeting, ultimately enhancing intracellular delivery of the aforementioned nucleic acids.